Director at Solid Biosciences (NASDAQ: SLDB) exercises RSUs

Rhea-AI Filing Summary

Solid Biosciences Inc. director Ian F. Smith exercised restricted stock units into common shares. On April 2, 2026 he converted 3,441 restricted stock units into 3,441 shares of common stock at a stated price of $0.00 per share.

The restricted stock units were granted on January 2, 2026 and vest in equal quarterly installments over 12 months from the grant date. Following this transaction, Smith holds 134,705 shares of common stock directly and 10,320 restricted stock units.

Insider Trade Summary

3,441 shares exercised/converted

Mixed 2 txns

Insider SMITH IAN F

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	3,441	$0.00	--
Exercise	Common Stock	3,441	$0.00	--

Holdings After Transaction: Restricted Stock Units — 10,320 shares (Direct); Common Stock — 134,705 shares (Direct)

Footnotes (1)

1. Restricted stock units convert to common stock on a one-for-one basis. The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

Key Figures

RSUs exercised: 3,441 units Common shares acquired: 3,441 shares Common shares after transaction: 134,705 shares +2 more

5 metrics

RSUs exercised 3,441 units Restricted stock units converted to common stock on April 2, 2026

Common shares acquired 3,441 shares Common stock received from RSU conversion on April 2, 2026

Common shares after transaction 134,705 shares Direct holdings of Ian F. Smith following the RSU conversion

RSUs remaining 10,320 units Restricted stock units held after the reported Form 4 transactions

RSU grant date January 2, 2026 Grant date for restricted stock units vesting in equal quarterly installments

Key Terms

Restricted Stock Units, derivative security, exercise or conversion, vesting

4 terms

Restricted Stock Units financial

"Restricted stock units convert to common stock on a one-for-one basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

exercise or conversion financial

"transaction_action: derivative exercise/conversion"

vesting financial

"vested in equal quarterly installments beginning three months from the date of grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH IAN F

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MASSACHUSETTS 02129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/02/2026		M		3,441	A	(1)	134,705	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	04/02/2026		M			3,441	(2)	(2)	Common Stock	3,441	$0.00	10,320	D

Explanation of Responses:

1. Restricted stock units convert to common stock on a one-for-one basis.

2. The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

	/s/ Kimberly Cornwell as attorney-in-fact for Ian F. Smith	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Solid Biosciences (SLDB) report for Ian F. Smith?

Ian F. Smith exercised 3,441 restricted stock units into 3,441 common shares. The units converted on April 2, 2026 at a stated price of $0.00 per share, reflecting a routine equity compensation vesting event for a company director.

How many Solid Biosciences (SLDB) shares does Ian F. Smith hold after this Form 4?

After the transaction, Ian F. Smith directly holds 134,705 common shares. He also holds 10,320 restricted stock units. These figures show his ongoing equity stake in Solid Biosciences following the April 2, 2026 restricted stock unit conversion.

What are the terms of the restricted stock units in this Solid Biosciences (SLDB) filing?

The restricted stock units convert to common stock on a one-for-one basis. They were granted on January 2, 2026 and vest in equal quarterly installments over 12 months, beginning three months from the grant date, providing staged equity compensation.

Was the Solid Biosciences (SLDB) insider transaction a purchase or an option exercise?

The transaction was an exercise or conversion of a derivative security, not an open-market purchase. Restricted stock units were converted into common shares at a stated price of $0.00, reflecting equity compensation vesting rather than a cash stock purchase.

How many restricted stock units does Ian F. Smith retain in Solid Biosciences (SLDB)?

Following the reported transaction, Ian F. Smith holds 10,320 restricted stock units. These units represent additional potential common shares subject to vesting terms described in the grant, which call for equal quarterly vesting over a 12-month period from January 2, 2026.